Frontiers in Immunology (Sep 2019)

Complement Inhibitors in Clinical Trials for Glomerular Diseases

  • Peter F. Zipfel,
  • Peter F. Zipfel,
  • Thorsten Wiech,
  • Ramona Rudnick,
  • Sara Afonso,
  • Fermin Person,
  • Christine Skerka

DOI
https://doi.org/10.3389/fimmu.2019.02166
Journal volume & issue
Vol. 10

Abstract

Read online

Defective complement action is a cause of several human glomerular diseases including atypical hemolytic uremic syndrome (aHUS), anti-neutrophil cytoplasmic antibody mediated vasculitis (ANCA), C3 glomerulopathy, IgA nephropathy, immune complex membranoproliferative glomerulonephritis, ischemic reperfusion injury, lupus nephritis, membranous nephropathy, and chronic transplant mediated glomerulopathy. Here we summarize ongoing clinical trials of complement inhibitors in nine glomerular diseases and show which inhibitors are used in trials for these renal disorders (http://clinicaltrials.gov).

Keywords